Treatment-Resistant Depression (TRD) stands as one of the most stubborn and costly challenges in modern healthcare. For the millions of patients who have cycled through multiple antidepressants without relief, the treatment landscape has long been a graveyard of failed promises.
ESTERO, Fla., Jan. 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Mushrooms, Inc. (OTC: MSRM), a U.S.
PROVO, UT / ACCESSWIRE / June 25, 2024 / Announcing the launch of Adaptin, a new wellness brand extending the benefits of functional adaptogens and nootropics to consumers globally through new marketing pathways. The new company brings innovation to both the formulations and the way products are shared in the growing adaptogen and functional mushroom dietary supplements, valued in the US at USD $40B in 2023, and a part of the rapidly growing USD $5.7T global wellness market.
| Food Products Industry | Consumer Staples Sector | Kimberly Carlson CEO | OTC PINK Exchange | 56782M107 CUSIP |
| US Country | 6 Employees | - Last Dividend | 29 Apr 2019 Last Split | - IPO Date |
Mushrooms Inc., originally founded as Marijuana Strategic Ventures Inc. in 2002, is a company based in Bonsall, California, that has pivoted its strategic focus towards the mushroom industry. In October 2022, it underwent a significant rebranding by changing its name to more accurately reflect its new direction. The company aims to grow by acquiring and merging with small, mid-sized, and development stage companies that operate within the mushroom sector. This strategic shift illustrates Mushrooms Inc.'s commitment to capitalizing on the burgeoning market opportunities within the mushroom industry, leveraging its expertise and resources to foster growth and innovation.
Mushrooms Inc. specializes in the following products and services, aimed at expanding its footprint within the mushroom industry: